Literature DB >> 10843939

Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture.

P K Jeffery1.   

Abstract

At least three conditions contribute to COPD. (1) Chronic bronchitis (mucous hypersecretion) is an inflammatory condition in which CD8+ T-lymphocytes, neutrophils, and CD68+ monocytes/macrophages predominate. The condition is defined clinically by the presence of chronic cough and recurrent increases in bronchial secretions sufficient to cause expectoration. There is enlargement of mucus-secreting glands and goblet cell hyperplasia, which can occur in the absence of airflow limitation. (2) Adult chronic bronchiolitis (small or peripheral airways disease) is an inflammatory condition of small bronchi and bronchioli in which there are predominantly CD8+ and pigmented macrophages. The functional defect is difficult to detect clinically but may be recognized by sophisticated tests of small airway function. There is mucous metaplasia, enlargement of the mass of bronchiolar smooth muscle, and loss of alveolar attachments. (3) Emphysema is an inflammatory condition of the alveoli in which T-lymphocytes, neutrophils, and pigmented alveolar macrophages are involved, associated with the release of excessive amounts of elastases. It is defined anatomically by permanent, destructive enlargement of airspaces distal to terminal bronchioli without obvious fibrosis. In contrast, asthma is a clinical syndrome characterized by allergic inflammation of bronchi and bronchioli in which CD4+ (helper) T-lymphocytes and eosinophils predominate. There is increased production and release of interleukin (IL)-4 and IL-5, which is referred to as a Th2-type response. There is usually increased tracheobronchial responsiveness to a variety of stimuli, and the condition is usually manifest as variable airflow obstruction. While differences between COPD and asthma have been highlighted, new data are emerging that indicate there may also be similarities.

Entities:  

Mesh:

Year:  2000        PMID: 10843939     DOI: 10.1378/chest.117.5_suppl_1.251s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

1.  Prediction of chronic obstructive pulmonary disease (COPD) in asthma patients using electronic medical records.

Authors:  Blanca E Himes; Yi Dai; Isaac S Kohane; Scott T Weiss; Marco F Ramoni
Journal:  J Am Med Inform Assoc       Date:  2009-03-04       Impact factor: 4.497

2.  Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.

Authors:  Huifeng Yu; Anabel Gonzalez-Gil; Yadong Wei; Steve M Fernandes; Ryan N Porell; Katarina Vajn; James C Paulson; Corwin M Nycholat; Ronald L Schnaar
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

3.  Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype.

Authors:  Lennart K A Lundblad; John Thompson-Figueroa; Timothy Leclair; Michael J Sullivan; Matthew E Poynter; Charles G Irvin; Jason H T Bates
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

4.  CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.

Authors:  Alexandre Trifilieff; Thomas H Keller; Neil J Press; Trevor Howe; Peter Gedeck; David Beer; Christoph Walker
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

5.  Klotho Reduction in Alveolar Macrophages Contributes to Cigarette Smoke Extract-induced Inflammation in Chronic Obstructive Pulmonary Disease.

Authors:  Lingling Li; Yujie Wang; Wei Gao; Cheng Yuan; Sini Zhang; Hong Zhou; Mao Huang; Xin Yao
Journal:  J Biol Chem       Date:  2015-09-18       Impact factor: 5.157

6.  Ectopic expressed miR-203 contributes to chronic obstructive pulmonary disease via targeting TAK1 and PIK3CA.

Authors:  Liang Shi; Qinghong Xin; Ruonan Chai; Lei Liu; Zhuang Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 7.  [Chronic obstructive lung disease].

Authors:  C Vogelmeier
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 8.  Therapy for chronic obstructive pulmonary disease in the 21st century.

Authors:  Louise E Donnelly; Duncan F Rogers
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype.

Authors:  Seyed Javad Moghaddam; Cecilia G Clement; M Miguelina De la Garza; Xiaoyan Zou; Elizabeth L Travis; Hays W J Young; Christopher M Evans; Michael J Tuvim; Burton F Dickey
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-20       Impact factor: 6.914

10.  SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease.

Authors:  Saravanan Rajendrasozhan; Se-Ran Yang; Vuokko L Kinnula; Irfan Rahman
Journal:  Am J Respir Crit Care Med       Date:  2008-01-03       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.